Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome.
Jaclyn D RosenzweigPallavi M PillaiSusan ProckopRyma BenayedLisa Eidenschink BrodersenVesna NajfeldMichael R LokenYanming ZhangNeerav N ShuklaPublished in: Cold Spring Harbor molecular case studies (2022)
Myeloid leukemia of Down syndrome (ML-DS) in young children is associated with distinct clinical and biological features and is typically initiated with oncogenic mutations in the X-linked megakaryocytic transcription factor GATA1. Here we present a 3-yr-old child with DS diagnosed with acute myeloid leukemia (AML), which lacks typical immunophenotypic and molecular characteristics of ML-DS, including GATA1 mutations. The leukemic blasts were found to have an MN1-ETV6 gene fusion, a high-risk oncofusion not previously described in DS patients. This report highlights the importance of immunophenotypic, cytogenetic, and molecular characterization of ML-DS for identification of rare cases with unique features that may benefit from treatment protocols that are more intensive than those developed for patients with typical GATA1 mutant ML-DS.
Keyphrases
- acute myeloid leukemia
- transcription factor
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- acute lymphoblastic leukemia
- mental health
- chronic kidney disease
- newly diagnosed
- genome wide identification
- bone marrow
- ejection fraction
- dna binding
- peritoneal dialysis
- prognostic factors
- genome wide
- gene expression
- immune response
- patient reported outcomes
- combination therapy
- single molecule
- wild type